

# Eiichi Ogawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4828886/publications.pdf>

Version: 2024-02-01

134  
papers

3,069  
citations

172207

29  
h-index

182168

51  
g-index

140  
all docs

140  
docs citations

140  
times ranked

3682  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 389-398.	3.7	616
2	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study. <i>Journal of Hepatology</i> , 2013, 58, 495-501.	1.8	126
3	The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. <i>Antiviral Research</i> , 2009, 83, 127-134.	1.9	123
4	Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7036-7041.	3.3	100
5	Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 104-113.	1.9	94
6	Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. <i>Hepatology Research</i> , 2007, 37, 1002-1010.	1.8	79
7	Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2004, 91, 498-503.	2.9	78
8	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.2	72
9	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. <i>Hepatology International</i> , 2021, 15, 366-379.	1.9	71
10	Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. <i>Hepatology</i> , 2020, 71, 1910-1922.	3.6	70
11	Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 205-212.	1.8	69
12	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 473-485.	1.8	62
13	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	1.9	58
14	Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. <i>Hepatology Research</i> , 2011, 41, 1178-1188.	1.8	55
15	Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial. <i>Journal of Hepatology</i> , 2012, 57, 1186-1192.	1.8	52
16	Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 550-562.	1.9	52
17	Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. <i>Journal of Hepatology</i> , 2013, 59, 667-674.	1.8	49
18	NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. <i>Journal of Gastroenterology</i> , 2017, 52, 845-854.	2.3	46

#	ARTICLE	IF	CITATIONS
19	Serum $\alpha$ -fetoprotein (AFP) is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting antiviral-based triple therapy for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 114-124.	1.9	44
20	Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. <i>JAMA Network Open</i> , 2020, 3, e201844.	2.8	42
21	Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. <i>Antiviral Research</i> , 2016, 136, 37-44.	1.9	41
22	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	1.9	38
23	Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. <i>Liver International</i> , 2020, 40, 1578-1589.	1.9	38
24	Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. <i>Journal of Hepatology</i> , 2012, 57, 534-540.	1.8	37
25	Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. <i>Liver International</i> , 2018, 38, 76-83.	1.9	37
26	Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study. <i>Hepatology Research</i> , 2019, 49, 617-626.	1.8	36
27	Evaluation of the adverse effect of premature discontinuation of pegylated interferon $\alpha$ 2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1233-1240.	1.4	34
28	Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: Results from the Kyushu and Okinawa Population Study (KOPS). <i>Atherosclerosis</i> , 2015, 238, 207-212.	0.4	33
29	Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. <i>Hepatology Research</i> , 2017, 47, E120-E131.	1.8	32
30	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	2.9	30
31	The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice. <i>Biochemical and Biophysical Research Communications</i> , 2011, 404, 115-120.	1.0	27
32	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	1.9	27
33	Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection. <i>Journal of Infection and Chemotherapy</i> , 2008, 14, 377-382.	0.8	26
34	Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2015, 21, 2116-2123.	1.4	25
35	Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 713-722.	1.9	25
36	Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3197-3204.	2.0	24

#	ARTICLE	IF	CITATIONS
37	Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. <i>Antiviral Research</i> , 2018, 159, 143-152.	1.9	24
38	Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1076-1085.	1.9	23
39	Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays. <i>Antiviral Research</i> , 2013, 99, 119-124.	1.9	23
40	Hepatitis B Virus Reactivation Potentiated by Biologics. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 341-358.	1.9	22
41	Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 1387.	1.4	21
42	Ribavirin concentration in the later stages of 48 week pegylated interferon- $\alpha$ 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1127-1139.	1.3	20
43	Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 866-876.	1.9	20
44	Secondary Syphilis with Pulmonary Involvement. <i>Internal Medicine</i> , 2018, 57, 121-126.	0.3	19
45	The spontaneously diabetic Torii rat with gastroenteropathy. <i>Diabetes Research and Clinical Practice</i> , 2007, 75, 127-134.	1.1	18
46	Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 483-490.	1.3	17
47	The serum undercarboxylated osteocalcin level and the diet of a Japanese population: results from the Kyushu and Okinawa Population Study (KOPS). <i>Endocrine</i> , 2013, 43, 635-642.	1.1	14
48	The utility of urinary myo-inositol as a marker of glucose intolerance. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 88-96.	1.1	14
49	Hepatitis B Virus-related Immune Reconstitution Inflammatory Syndrome in Two Patients Coinfected with Human Immunodeficiency Virus Diagnosed with a Liver Biopsy. <i>Internal Medicine</i> , 2014, 53, 2165-2170.	0.3	14
50	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	1.9	14
51	Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000209.	1.1	13
52	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. <i>American Journal of Gastroenterology</i> , 2021, 116, 1264-1273.	0.2	12
53	Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1759-1767.	1.4	11
54	Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 15.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study. <i>Archives of Virology</i> , 2016, 161, 641-648.	0.9	11
56	Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000207.	1.1	11
57	Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. <i>Cancers</i> , 2021, 13, 3455.	1.7	11
58	Protein-losing enteropathy during highly active antiretroviral therapy in a patient with AIDS-related disseminated Mycobacterial avium complex infection. <i>Journal of Infection and Chemotherapy</i> , 2009, 15, 252-256.	0.8	10
59	Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. <i>BMC Gastroenterology</i> , 2010, 10, 38.	0.8	10
60	Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. <i>Antiviral Research</i> , 2014, 104, 102-109.	1.9	10
61	Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1309-1316.	1.4	10
62	The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 147-156.	0.5	10
63	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Liver International</i> , 2022, 42, 59-68.	1.9	10
64	Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 28-32.	0.8	9
65	Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C. <i>Cancers</i> , 2020, 12, 2602.	1.7	9
66	Non-Invasive Fibrosis Assessment Predicts Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 185-192.	0.6	8
67	Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV Assays for the Monitoring of Sofosbuvir-Based Therapy. <i>Antiviral Therapy</i> , 2017, 22, 61-70.	0.6	8
68	Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis. <i>Hepatology Research</i> , 2020, 50, 174-181.	1.8	8
69	Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals. <i>Journal of Infectious Diseases</i> , 2020, , .	1.9	8
70	Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients. <i>Gut and Liver</i> , 2011, 5, 447-453.	1.4	8
71	Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1408-1408.	1.9	7
72	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	1.9	7

#	ARTICLE	IF	CITATIONS
73	Nocturnal Difference in the Ultra Low Frequency Band of Heart Rate Variability in Patients Stratified by Kampo Medicine Prescription. <i>Circulation Journal</i> , 2014, 78, 1924-1927.	0.7	6
74	Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. <i>Journal of Viral Hepatitis</i> , 2015, 22, 992-1001.	1.0	6
75	A case of Fanconi's syndrome caused by long-term administration of adefovir by a patient with chronic hepatitis B. <i>Acta Hepatologica Japonica</i> , 2013, 54, 187-193.	0.0	6
76	Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 371-377.	1.4	6
77	A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 577-581.	0.8	5
78	The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfecting patients. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 264-271.	0.8	5
79	Toxocariasis Suspected of Having Infiltrated Directly from the Liver to the Lung through the Diaphragm. <i>Internal Medicine</i> , 2019, 58, 2737-2741.	0.3	5
80	Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2011, 17, 2945.	1.4	5
81	Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. <i>Hepatology International</i> , 2022, 16, 282-293.	1.9	5
82	Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. <i>Journal of Infection and Chemotherapy</i> , 2011, 17, 737-743.	0.8	4
83	An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 689-697.	0.8	4
84	A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon- $\alpha$ and ribavirin therapy. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 320-324.	0.8	4
85	Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection. <i>Internal Medicine</i> , 2015, 54, 567-572.	0.3	4
86	Efficacy of interferon- $\beta$ plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. <i>Hepatology Research</i> , 2016, 46, E174-80.	1.8	4
87	Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy. <i>Antiviral Research</i> , 2016, 126, 35-42.	1.9	4
88	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	2.4	4
89	Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 4696-4706.	1.4	4
90	A case report of human immunodeficiency virus-associated anaplastic lymphoma kinase protein-negative anaplastic large cell lymphoma. <i>SpringerPlus</i> , 2013, 2, 400.	1.2	3

#	ARTICLE	IF	CITATIONS
91	820 THERAPEUTIC DRUG MONITORING OF TELAPREVIR IN CHRONIC HEPATITIS C PATIENTS RECEIVING TELAPREVIR-BASED TRIPLE THERAPY IS USEFUL FOR PREDICTING VIROLOGICAL RESPONSE AND AVOIDING TOXIC DRUG-EXPOSURE. <i>Journal of Hepatology</i> , 2013, 58, S336.	1.8	3
92	Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide. <i>Endocrine</i> , 2013, 43, 200-205.	1.1	3
93	Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1728-1735.	1.4	3
94	The relation of postprandial plasma glucose and serum endostatin to the urinary albumin excretion of residents with prediabetes: results from the Kyushu and Okinawa Population Study (KOPS). <i>International Urology and Nephrology</i> , 2016, 48, 851-857.	0.6	3
95	Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C. <i>Infectious Agents and Cancer</i> , 2016, 11, 9.	1.2	3
96	Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 190-199.	1.4	3
97	A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	3
98	1144 COMPLETE HEPATITIS C VIRUS ELIMINATION DURING PEGYLATED INTERFERON $\alpha$ 2B AND RIBAVIRIN TREATMENT REDUCES THE RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2012, 56, S452.	1.8	2
99	Interferon- $\gamma$ -Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections. <i>Hepatitis Research and Treatment</i> , 2013, 2013, 1-7.	2.0	2
100	Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia. <i>Journal of Viral Hepatitis</i> , 2013, 20, 838-846.	1.0	2
101	Environmental Infections, 2008, 23, 1-7.		
102	Kyushu and Okinawa Population Study (KOPS): a large prospective cohort study in Japan. <i>BMJ Open</i> , 2021, 11, e053763.	0.8	2
103	1197 INSULIN RESISTANCE UNDERMINES THE ADVANTAGES OF IL28B POLYMORPHISM IN THE PEGYLATED INTERFERON $\alpha$ 2B AND RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1. <i>Journal of Hepatology</i> , 2012, 56, S474-S475.	1.8	1
104	886 IMPACT OF THE VIRAL KINETICS OF CHRONIC HEPATITIS C PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON $\alpha$ 2b AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2013, 58, S365.	1.8	1
105	The Safety and Efficacy of Direct-Acting Antiviral Treatment for Patients with Genotype 1 Chronic Hepatitis C and Renal Impairment. <i>Journal of Hepatology</i> , 2016, 64, S801-S802.	1.8	1
106	Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting antivirals in terms of prediction of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 122-123.	1.9	1
107	Editorial: FAST score—a new predictive marker for HCC after SVR—author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1224-1224.	1.9	1
108	Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication. <i>Journal of Medical Virology</i> , 2022, 94, 5007-5014.	2.5	1

#	ARTICLE	IF	CITATIONS
109	Oral and Poster Papers Submitted for Presentation at the 5th Congress of the EUGMS "Geriatric Medicine in a Time of Generational Shift September 3-6, 2008 Copenhagen, Denmark. Journal of Nutrition, Health and Aging, 2008, 12, 545-593.	1.5	0
110	1112RALOXIFENE HYDROCHLORIDE AS A NOVEL ANTIVIRAL AGENT: INHIBITION OF HEPATITIS C VIRUS (HCV) REPLICATION. Journal of Hepatology, 2012, 56, S438.	1.8	0
111	Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: Is it really the effect of the therapy?" Journal of Hepatology, 2013, 58, 839-840.	1.8	0
112	Nocturnal Difference in Ultra-Low Frequency Band of the Heart Rate Variability of Patients Stratified by Kampo Medicine Prescription. Journal of Alternative and Complementary Medicine, 2014, 20, A91-A91.	2.1	0
113	P1170 VIROLOGICAL RESPONSE AT WEEK 6 OF TELAPREVIR-BASED TRIPLE THERAPY IS THE MOST EFFECTIVE PREDICTOR OF CHRONIC HEPATITIS C TREATMENT OUTCOME. Journal of Hepatology, 2014, 60, S474.	1.8	0
114	P1103 IMPACT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL ON RESPONSE TO TELAPREVIR-BASED TRIPLE THERAPY FOR CHRONIC HEPATITIS C PATIENTS. Journal of Hepatology, 2014, 60, S445-S446.	1.8	0
115	P1108 EFFICACY AND TOLERABILITY OF TELAPREVIR-BASED TRIPLE THERAPY FOR ADVANCED FIBROSIS STAGE CHRONIC HEPATITIS C PATIENTS: RESULTS OF THE KYUSHU UNIVERSITY LIVER DISEASE STUDY GROUP. Journal of Hepatology, 2014, 60, S447.	1.8	0
116	P0833 : Simeprevir- and telaprevir-based triple therapies for genotype 1b chronic hepatitis C patients aged 70 and over in a multicentre cohort study. Journal of Hepatology, 2015, 62, S649.	1.8	0
117	P0845 : Comparative study on the effectiveness of simeprevir or telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1b infection. Journal of Hepatology, 2015, 62, S655-S656.	1.8	0
118	A case of granulomatosis with polyangiitis preceded by subacute thyroiditis. Clinical Case Reports (discontinued), 2015, 3, 139-144.	0.2	0
119	Subclinical carotid atherosclerosis predicts the incidence of chronic kidney disease in a Japanese general population. Atherosclerosis, 2015, 241, e64-e65.	0.4	0
120	Raloxifene improves arterial stiffness and the carotid IMT progression in postmenopausal osteopenia/osteoporosis women over 12 months. Atherosclerosis, 2015, 241, e145.	0.4	0
121	Rapid Decrease of the Non-Invasive Serum Liver Fibrosis Marker WFA+-M2BP by IFN-Free Therapy. Journal of Hepatology, 2016, 64, S726-S727.	1.8	0
122	Effectiveness and Safety of Sofosbuvir and Ribavirin for Elderly Patients with HCV Genotype 2 Infection. Journal of Hepatology, 2016, 64, S759-S760.	1.8	0
123	A case of amebiasis with negative serologic markers that caused intra-abdominal abscess. Journal of Infection and Chemotherapy, 2017, 23, 778-781.	0.8	0
124	Factors that influence the improvement of serum albumin during interferon-free sofosbuvir/ledipasvir therapy for Japanese patients with chronic hepatitis C virus infection. Journal of Hepatology, 2017, 66, S280-S281.	1.8	0
125	Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with hepatitis C virus genotype 1b or 2 infection: real life experience from a multicenter cohort. Journal of Hepatology, 2017, 66, S308.	1.8	0
126	Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis. Journal of Hepatology, 2018, 68, S259-S260.	1.8	0



#	ARTICLE	IF	CITATIONS
127	Validation of AASLD treatment guideline eligibility based on disease outcomes of large community and clinical cohorts of chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2018, 68, S503.	1.8	0
128	Efficacy and safety of direct-acting antivirals for 1,961 Japanese chronic hepatitis C patients – Real World Data from a multicenter cohort. <i>Journal of Hepatology</i> , 2018, 68, S286.	1.8	0
129	Validation of a clinical scoring system to predict risk of hepatocellular carcinoma in an ethnically diverse cohort of patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2018, 68, S305-S306.	1.8	0
130	Estimated the number of undiagnosed patients and antiviral treatment rate of chronic hepatitis B in the U.S. based on the Truven Health MarketScan Database. <i>Journal of Hepatology</i> , 2018, 68, S481-S482.	1.8	0
131	Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort. <i>Journal of Hepatology</i> , 2018, 68, S549-S550.	1.8	0
132	Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. <i>BMJ Open</i> , 2019, 9, e023405.	0.8	0
133	Tongue Color as an Indicator of Gastroesophageal Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, S598.	0.2	0
134	Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. <i>World Journal of Hepatology</i> , 2015, 7, 2688.	0.8	0